Therapeutic agents
US5627191A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 21, 1995 |
| Grant date | May 6, 1997 |
| Priority date | — |
| Expiry date | Feb 21, 2015 |
Classification
- Technology area (CPC H)Electricity
- CPC primaryH05K3/26
- WIPO fieldBasic materials chemistry
- WIPO sectorChemistry
Abstract
The invention provides compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof; wherein R.sub.50 is hydrogen or C.sub.1-4 alkyl, A.sub.51 is oxygen, sulphur or a group of the formula --NR.sub.52 -- wherein R.sub.52 is hydrogen or C.sub.1-4 alkyl; A.sub.50 comprises i) a mono or bicyclic aromatic ring optionally containing one or more nitrogen, oxygen or sulphur atoms, ii) a cycloalkendiyl group, or iii) an acyclic bridging group having a chain of one, two or three atoms between the cyclobutenedione group and X.sub.50, said chain being a chain of one or two carbon atoms or a chain of one carbon atom and one or more nitrogen, oxygen or sulphur atoms or iv) a bond; X.sub.50 is either a bond or a spacer group providing a chain between A.sub.50 and B.sub.50 of one or two atoms length; B.sub.50 is a mono or bicyclic aromatic-ring optionally containing one or more nitrogen, oxygen or sulphur atoms; r is an integer from 1 to 6; and Het is a ring system optionally containing one or more nitrogen, oxygen or sulphur atoms or is a phosphonate, phosphinate or amine derivative (wherein each of A.sub.50, X.sub.50, B.sub.50 and Her are optionally substituted). The compounds h…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.